Dermbits

Summary In the video, Dr. Darrell Rigel discusses the significance of better assessing the prognosis of squamous cell carcinoma (SCC), including cutaneous SCC. He emphasizes that SCC is a serious disease and can lead to fatalities. Therefore, it is crucial to have an accurate prognosis assessment to determine which patients require further therapy. Understanding the prognosis allows healthcare professionals to provide appropriate and timely treatment for those affected by SCC. Key Points Squamous cell carcinoma (SCC) is a serious disease, including cutaneous squamous cell carcinoma, and it can lead to fatalities. Accurate assessment of SCC prognosis is essential to determine the appropriate course of action for patients, including the need for further therapy. Prognosis assessment helps in identifying high-risk patients who may require more intensive treatments and monitoring. Early identification of patients with poor prognosis can potentially improve outcomes and increase survival rates. Tailoring treatment plans based on prognosis can help avoid over-treatment in low-risk cases and provide more aggressive approaches for high-risk cases. Monitoring prognosis allows healthcare professionals to make informed decisions and adjustments in treatment strategies as the disease progresses. Improved prognosis assessment contributes to a more personalized and effective approach to managing SCC patients. Research and advancements in prognosis assessment may lead to better understanding of SCC's behavior and potential new treatment options. Overall, accurate prognosis assessment is crucial for enhancing the management and outcomes of individuals with SCC.

Summary In the video, Dr. Darrell Rigel explains how the 40-GEP test functions. The test involves the analysis of 40 specific genes to evaluate their expression levels. These genes are used in combination with a proprietary formula to determine a patient's prognosis. Based on the results, patients are categorized into low-risk, medium-risk, or high-risk groups. This classification helps medical professionals make more accurate assessments and tailor the appropriate treatment plan accordingly. Key Points The 40-GEP test utilizes 40 specific genes. Its primary purpose is to assess prognosis in medical cases. The test evaluates the degree of gene expression in combination with a proprietary formula. The evaluation helps categorize patients into different risk groups: low risk, medium risk, or high risk. The results of the test allow healthcare professionals to tailor treatment plans based on the risk group the patient falls into. By understanding the patient's risk level, the therapy can be adjusted accordingly to optimize treatment outcomes.

Summary In this video, Dr. Darrell Rigel addresses the question of which squamous cell carcinomas (SCCs) are suitable for the 40-GEP test. He emphasizes that not all SCCs are appropriate for this particular test. The data used to develop the test was gathered from cases of advanced squamous cell carcinomas, specifically those that have at least one of the high-risk factors such as large diameter, significant depth, and other risk factors associated with advanced disease. The 40-GEP test is not intended for use with squamous cell carcinoma in situ or early-stage squamous cell carcinomas. Instead, it is specifically designed and validated for cases where there are indicators of advanced disease. Key Points SCCs (Squamous Cell Carcinomas) that are appropriate for the 40-GEP (Gene Expression Profiling) test are specific types of cases. The test's data was collected on advanced squamous cell carcinomas, which means it is not suitable for squamous cell carcinoma in situ (early stage) cases. It is specifically designed for squamous cell carcinomas that have at least one of the high-risk factors associated with advanced disease. The high-risk factors include diameter, depth, and other risk factors that indicate the likelihood of the carcinoma being in an advanced stage.

Summary Dr. Darrell Rigel discusses how he approaches the discussion of 40-GEP (Genomic Expression Profile) test results with his patients. He emphasizes the importance of having a frank conversation with the patients about their test results. The 40-GEP test results are relatively easy for patients to understand because they are categorized into three levels of risk: low risk, mid-risk, and high risk. Depending on which risk category the patient falls into, Dr. Rigel tailors his discussion accordingly. For patients with low-risk results, Dr. Rigel can confidently inform them that there is no need for advanced treatments or additional therapies beyond close monitoring. However, for patients in the mid-risk or high-risk category, he may discuss the possibility of additional therapies such as adjuvant radiation or the use of specific medications like cemiplimab, PD1 inhibitors, or other more advanced treatments. The primary goal of discussing these test results with patients is to provide them with a clear understanding of their risk level and prognosis. This information allows for informed decision-making regarding the necessity and potential benefits of further treatment options, ensuring the best possible care for each individual patient. Key Points 40-GEP test results are easy for patients to understand as they are categorized into three levels of risk: low, mid risk, and high risk. The degree of risk and prognosis are used to determine whether additional therapy is necessary, and the doctor should tailor their discussion with the patient accordingly. Treatment options discussed with mid to high-risk patients may include adjuvant radiation, cemiplimab, PD1 inhibitors, or more advanced treatments. For low-risk patients, the need for advanced treatments is deemed unnecessary, and close patient monitoring may suffice.

Summary In the video, Dr. Darrell Rigel addresses the question of whether the 40-GEP test is covered by Medicare. He explains that currently, there is insurance coverage available for some cases, but the specific coverage rules may vary depending on the Medicare coverage carrier. He mentions that over time, the coverage for the 40-GEP test is expected to become more clear and standardized. Dr. Rigel also mentions that the company offering the 40-GEP test accepts insurance as a form of payment. This approach is designed to make it easier for patients to access the test results without facing financial burdens. Key Points The 40-GEP test may be covered by Medicare, but the coverage is not consistent across all cases. Different Medicare coverage carriers have varying rules regarding the 40-GEP test's insurance coverage. The insurance coverage situation is expected to become more clear and standardized at some point in the future. The company conducting the 40-GEP test accepts insurance as a form of payment from patients.

Summary In the video "Why doesn't SCC get the respect it should?" Dr. Darrell Rigel discusses the lack of recognition that cutaneous squamous cell carcinoma (SCC) receives in comparison to other types of skin cancer. He likens SCC to the "Rodney Dangerfield" of skin cancer, meaning it doesn't receive the respect it deserves. The reason for this lack of recognition is that SCC falls in the middle between basal cell carcinoma (which has lower risk) and melanoma (which has a much higher risk). However, Dr. Rigel points out that the data shows almost as many people die from cutaneous squamous cell carcinoma in the United States as from melanoma. Although the percentage of SCC-related deaths may be lower due to the higher prevalence of SCC cases, the actual number of deaths is significant. This underscores the importance of better assessing the prognosis of cutaneous squamous cell carcinoma to raise awareness about its severity and address its impact on public health effectively. Key Points SCC (Squamous Cell Carcinoma) is often overlooked and does not receive the respect it deserves. One of the reasons for SCC's lack of attention is because it falls in the middle when comparing it to other skin cancers. Basal cell carcinoma is considered less risky, while melanoma is regarded as a higher-risk skin cancer. However, Dr. Rigel emphasizes the importance of recognizing that SCC is still a significant concern. In the United States, the number of deaths from cutaneous squamous cell carcinoma is almost as high as that of melanoma. The lower percentage of SCC-related deaths compared to melanoma can be attributed to the higher number of SCC cases overall (more contagious squamous cells). Dr. Rigel stresses the need to improve the assessment of prognosis for SCC to better understand and address its impact on public health.

Summary In the video, Dr. Darrell Rigel discusses the traditional prognostic paradigms for squamous cell carcinoma (SCC). Currently, the two commonly used criteria are the AJCC (American Joint Committee on Cancer) criteria and the Boston Women and Brigham's criteria. These criteria rely on assessing clinical and histopathologic factors such as the diameter of the lesion and the presence of perineural invasion, among other factors. However, Dr. Rigel points out that these traditional paradigms do not take into account genomic information. This is where the 40-GEP test comes into play. The 40-GEP test provides additional genomic information, which can be integrated into the prognosis assessment to improve accuracy. By incorporating genomic data, clinicians can gain valuable insights into the underlying genetic characteristics of SCC, leading to a more comprehensive and refined prognosis for patients. This advancement in prognostic evaluation may ultimately aid in better treatment decision-making and patient outcomes. Key Points Traditional SCC prognostic paradigms: AJCC criteria, Boston Women, and Brigham’s criteria. Assessment of prognosis for squamous cell carcinoma based on clinical and histopathologic factors. Factors used in traditional criteria include diameter of the lesion and perineural invasion involvement. Traditional methods lack consideration of genomics in prognosis assessment. The 40-GEP test provides additional genomic information for better and more accurate prognosis integration.

Summary Dr. Darrell Rigel discusses the trends in the incidence of cutaneous squamous cell carcinoma (SCC) in the United States. He states that the incidence of SCC is consistently increasing, particularly in the southern half of the country. This rising trend highlights the need to improve the identification of patients who are at the highest risk of developing metastatic disease and facing death due to SCC. By identifying these high-risk patients, healthcare providers can administer more aggressive therapies to appropriately treat the condition and improve patient outcomes. Key Points Cutaneous squamous cell carcinoma (SCC) incidence is on the rise in the United States. The increase in SCC incidence is particularly notable in the southern half of the country. Identifying patients at the highest risk for metastatic disease and death is becoming increasingly important. The goal is to treat high-risk patients with more aggressive therapy to improve outcomes. The rising trend in SCC calls for improved methods of identifying and diagnosing high-risk patients. Early detection and appropriate treatment are crucial in managing SCC cases effectively.

Summary Dr. Darrell Rigel explains in the video that the ideal patient for the 40-GEP test is someone who has a more advanced tumor. The main objective of this test is to identify individuals at the highest risk for metastatic disease. A class 2B result from the test indicates the highest risk, with a likelihood of 50 to 60% for metastatic disease. Therefore, the test is most appropriate for patients who already have an advanced tumor and have other risk factors associated with it. The test was not specifically designed for individuals with early-stage squamous cell carcinoma or squamous cell in situ, as the data was not collected for such cases. In summary, the 40-GEP test is recommended for patients with more advanced disease and additional risk factors for metastatic progression. Key Points The 40-GEP test is designed for patients with a more advanced tumor. The purpose of the test is to identify those at the highest risk for metastatic disease. A class 2B result from the 40-GEP test indicates the highest risk, with a 50 to 60% chance of metastatic disease. The ideal patient for the test is someone who already has an advanced tumor to some extent and has other risk factors for metastasis. The test is not suitable for individuals with squamous cell in situ or very early squamous cell cancer, as the data for the test was not collected for such cases. The focus of the 40-GEP test is on patients with more advanced disease to provide meaningful results.

Summary In this video, Dr. Michael Cameron addresses the question of whether patients with alopecia areata are more likely to have other dermatologic conditions. He confirms that patients with alopecia areata indeed have a higher likelihood of experiencing other dermatologic conditions. One common comorbid condition seen with alopecia areata is atopic dermatitis. Dr. Cameron explains that autoimmune diseases, including alopecia areata, often run in families. Consequently, it's possible for family members to have different autoimmune conditions, such as thyroid disease or atopic dermatitis. Additionally, he mentions that the alopecia areata population frequently exhibits cases of eczema (atopic dermatitis). The video emphasizes the existence of these associations and suggests that understanding such connections may be helpful for clinicians in diagnosing and treating patients with alopecia areata. Key Points Patients with alopecia areata are more likely to have other dermatologic conditions. Comorbid conditions are common, with atopic dermatitis being a significant one. Autoimmune diseases often run in families, suggesting a genetic link. • There may be a pattern where certain family members have different autoimmune conditions, e.g., one family member having thyroid disease and another having atopic dermatitis. Among the AA (alopecia areata) population, eczema (atopic dermatitis) is frequently observed.

Summary In this video, Dr. Michael Cameron discusses the ORAL Surveillance study and its relevance to the labeling language of the drug Olumiant (baricitinib), particularly in dermatology practice. The ORAL Surveillance study was conducted to evaluate the safety of the JAK inhibitor tofacitinib in the rheumatoid arthritis (RA) population. The study specifically targeted high-risk patients, who were over the age of 50 and had at least one cardiovascular risk factor. All the RA patients in the study were also on methotrexate, with a median dose of 17 milligrams, and 60% of them were on chronic prednisone. This means the patients in this study were at a significantly higher risk compared to younger, healthier patients typically seen in dermatology, such as those with alopecia areata. Dr. Cameron emphasizes the importance of understanding the context and differences in patient populations when considering the safety of JAK inhibitors in dermatology. While the ORAL Surveillance study provided crucial safety data for tofacitinib in RA patients, the risks and safety profile may differ in dermatology patients who do not share the same high-risk characteristics. Despite this difference in patient populations, the labeling language of Olumiant, which is based on the ORAL Surveillance study, includes a boxed warning. Dr. Cameron points out that dermatology providers should be aware of the ORAL Surveillance study's context and the higher-risk profile of the RA patients involved. By understanding these distinctions, healthcare professionals can confidently and safely use JAK inhibitors in dermatology patients, even if the boxed warning is still present in the drug's labeling language. Key Points The ORAL Surveillance study focused on the JAK inhibitor tofacitinib in the rheumatoid arthritis (RA) population. The study included high-risk patients who were over 50 years old and had at least one cardiovascular risk factor. All RA patients in the study were on methotrexate with a median dose of 17 milligrams, and 60% were on chronic prednisone. The patient population in the study was markedly different from younger and healthier patients with conditions like alopecia areata. The safety profile of JAK inhibitors in dermatology is different from that observed in the RA population in the ORAL Surveillance study. Despite the differences in safety, the boxed warning language from the ORAL Surveillance study still applies to JAK inhibitors. Contextual understanding is necessary to ensure the safe use of JAK inhibitors in dermatology.

Summary In the video, Dr. Michael Cameron discusses the eligibility criteria for treatment with baricitinib and highlights some notable exclusion criteria. According to the label for baricitinib, it is defined as a treatment option for severe alopecia areata. However, there are no specific requirements regarding body surface area involvement. The decision of what constitutes severe alopecia areata and necessitates treatment with baricitinib is left to the provider and the patient to determine. In terms of exclusion criteria, it is not recommended to use baricitinib in combination with other systemic immunosuppressants such as methotrexate, prednisone, and azathioprine. This indicates that patients who are already taking these medications should not be considered for baricitinib treatment due to potential adverse effects or interactions. In summary, patients eligible for baricitinib treatment are those with severe alopecia areata, as determined by the provider and the patient, and who are not already taking an immunosuppressant. Key Points There are no specific body surface area involvement requirements for eligibility. The decision on whether a case of alopecia areata is considered severe and requires baricitinib treatment is made jointly by the healthcare provider and the patient. Baricitinib should not be used in combination with other systemic immunosuppressants such as methotrexate, prednisone, and azathioprine. Contraindications include concurrent use of baricitinib with certain medications that have immunosuppressive properties.

Summary In the video, Dr. Michael Cameron discusses the response patterns of patients with alopecia areata to the medication baricitinib. He points out that alopecia areata is composed of multiple diseases or different endotypes, leading to various response curves. Based on his experience with patients on baricitinib, he has observed a few different response patterns. According to Dr. Cameron, some patients may experience regrowth of hair as early as four weeks after starting treatment with baricitinib. However, he also notes that other patients may take up to nine months to see noticeable results. Therefore, he advises healthcare professionals to counsel their patients that it is possible to see a response within four weeks, but it could also take as long as nine months for the medication to show its effects on hair regrowth in cases of alopecia areata. Key Points Alopecia areata is a condition with multiple diseases or different endotypes, leading to varying response patterns in patients. Patients on baricitinib may experience different response curves. Some patients may start seeing regrowth as early as four weeks after starting treatment, where others may take as long as nine months to see results. Healthcare professionals should counsel patients that the time to see a response can vary.

-

Summary In this video, Dr. Michael Cameron explains the difference between the mechanism of action (MOA) of baricitinib and topical JAK (Janus kinase) inhibitors. He mentions that the MOA of both baricitinib and topical JAK inhibitors is essentially the same. However, the critical difference lies in their delivery methods. According to Dr. Cameron, he has personally tried using topical JAK inhibitors off-label for mild alopecia areata, but without success. The challenge with topical JAK inhibitors is developing a formulation that can consistently and effectively deliver the JAK inhibitor to the hair follicles where the disease occurs. On the other hand, the advantage of Olumiant (baricitinib) is that it is administered orally, allowing the JAK inhibitor to be delivered systemically. This enables it to reach the hair follicles where the disease is happening, potentially making it a more effective treatment for conditions like alopecia areata. In summary, the key difference between baricitinib and topical JAK inhibitors lies in their delivery methods, with baricitinib being an oral treatment that can reach the affected hair follicles more effectively. Key Points The mechanism of action (MOA) of baricitinib and topical JAK inhibitors is the same, but the critical difference lies in the delivery method. Baricitinib is advantageous because it is delivered orally, allowing the JAK inhibitor to reach the hair follicles where the disease is occurring. Developing a topical formulation that effectively delivers the JAK inhibitor to the hair follicle has been challenging, thus an advantage of baricitinib is that it is administered orally.

Summary In the video, Dr. Michael Cameron addresses the question of whether baricitinib can be used in combination with other biologics, JAK inhibitors, or immunosuppressants for the treatment of alopecia areata. According to Dr. Cameron, it is not recommended to use other immunosuppressants alongside baricitinib for alopecia areata. The label and data for baricitinib indicate that it should be used as a standalone treatment and should not be combined with other immunosuppressant medications. Key Points Baricitinib should not be used in combination with other immunosuppressants for alopecia areata. The label and data clearly indicate that using baricitinib alongside other immunosuppressants is not recommended. The video emphasizes the importance of avoiding the simultaneous use of other immunosuppressants with baricitinib for this condition.

Summary In the video, Dr. Michael Cameron discusses the recommended dosing regimen for baricitinib. He mentions that for most patients, the initial dosage should be two milligrams. However, if the patient has total or almost complete scalp hair loss or hair loss that involves the eyebrows or eyelashes, the label suggests starting with four milligrams. Once a response is achieved, it is advisable to consider reducing the dosage back to two milligrams. Key Points The majority of patients should start with two milligrams according to the label. If patients have total or almost complete scalp hair loss or eyebrow or eyelash involvement, they can start with four milligrams. After achieving a response, consider reducing the dosage back to two milligrams.

Summary Dr. Michael Cameron discusses the long-term safety data available for baricitinib, a drug used in the treatment of rheumatoid arthritis and alopecia areata. The drug has been in use for many years for rheumatoid arthritis, and now several years of data are available for its use in alopecia areata. Comparing the safety data with that of another drug, tofacitinib, used in rheumatoid arthritis, there are no significant safety signals seen for baricitinib. The safety signals observed with tofacitinib in a study for rheumatoid arthritis included issues like malignancy, clustering of organ systems for malignancy (lymphoma or lung cancers), cardiac events, blood clots, and an increased risk of serious infections, including shingles. However, in the case of baricitinib used for alopecia areata, there are no such signals. The safety profile for baricitinib in alopecia areata is described as "really, really clean" by Dr. Cameron. Overall, the data indicates that baricitinib appears to be safe for long-term use in treating alopecia areata, with no significant safety concerns observed in the studied period. Key Points Baricitinib has been used for many years in rheumatoid arthritis. There is now data available for baricitinib use in alopecia areata. The safety signals observed with tofacitinib use in rheumatoid arthritis are not seen with baricitinib in alopecia areata. No signal for malignancy or clustering of organ systems for malignancy (e.g., lymphoma or lung cancers) is observed. There are no significant cardiac events or blood clot risks associated with baricitinib use. There is no increased risk for serious infections, including shingles, with baricitinib use. The rate of adverse events with baricitinib is almost numerically equivalent to placebo, with only a slight increase observed. Baricitinib shows a very clean safety profile in alopecia areata.

Summary In the video, Dr. Raj Chovatiya addresses the question of whether ruxolitinib cream can be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants. According to the FDA approved prescribing information, ruxolitinib cream was studied and approved as a monotherapy. Therefore, the label indicates that it should not be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants. However, despite this indication on the label, real-world data from various sources, including Dr. Chovatiya's group, suggest that some individuals are combining ruxolitinib cream with other therapies successfully. This practice deviates from the approved label usage. Nevertheless, ongoing studies are being conducted to evaluate the efficacy and safety of using ruxolitinib cream in combination with other therapies. These studies aim to provide valuable insights into the potential benefits and risks of such combinations, ensuring informed and evidence-based treatment decisions for patients. Key Points Ruxolitinib cream was studied and approved as a monotherapy. The FDA-approved prescribing information for ruxolitinib cream indicates that it should not be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants. Despite the label indication, real-world data shows that some people are combining ruxolitinib cream with other therapies successfully, deviating from the approved usage. There are ongoing studies to determine the efficacy and safety of using ruxolitinib cream in combination with other therapies. These studies aim to provide more insights into the potential benefits and risks for individuals who use the cream in combination with other treatments.

Summary Dr. Raj Chovatiya discusses the limitations of other atopic dermatitis therapies and how ruxolitinib cream addresses these issues. Historically, topical therapies for atopic dermatitis have had some shortcomings. Topical corticosteroids, while effective, are considered a "blunt instrument" and may lead to various side effects, such as thinning of the skin, pigmentary issues, loss of subcutaneous fat, and potential systemic absorption of steroids. On the other hand, topical calcineurin inhibitors have modest potency and may cause adverse events like stinging and burning. There has also been concern about a potential risk of lymphomas, although this has not been supported in the long term. Therefore, there has been a need for a topical therapy that is safe, effective, and non-steroidal. Ruxolitinib cream appears to meet these requirements. It offers potency comparable to some of the stronger topical corticosteroids, and it has a favorable steroid-sparing effect. Furthermore, both clinical trial data and real-world evidence suggest that ruxolitinib cream is a safe option for managing atopic dermatitis. This addresses the limitations of previous therapies and provides a promising treatment alternative for those with the condition. Key Points Ruxolitinib cream addresses limitations of other atopic dermatitis therapies. Traditional topical therapies for atopic dermatitis have some gaps in their care and there is a general desire for a topical therapy that is safe, effective, and non-steroid-based. Topical corticosteroids are broadly acting but often associated with side effects like thinning of the skin, pigmentary issues, loss of subcutaneous fat, and potential systemic absorption of steroids. Topical calcineurin inhibitors have modest potency and can cause adverse events such as stinging and burning. Ruxolitinib cream offers potency comparable to strong topical corticosteroids and a steroid-sparing effect. Ruxolitinib cream's safety has been supported by both clinical trial data and real-world data.

Summary According to Dr. Raj Chovatiya, ruxolitinib cream has shown impressive itch reduction results both in clinical studies and real-world applications. Patients using the cream can expect to experience significant itch relief within minutes to hours after application. Dr. Chovatiya's clinical experience aligns with the findings from phase two trial programs, where patients reported fast and noticeable improvements in their itch scores shortly after using the cream. Key Points Ruxolitinib cream provides rapid itch reduction. Both real-world experiences and clinical studies have demonstrated the fast resolution of itch with ruxolitinib cream. The cream has been praised for its quick and effective action in reducing itch, as acknowledged by patients and healthcare professionals alike.

Summary In the video, Dr. Raj Chovatiya discusses the appropriate use and discontinuation of ruxolitinib cream, considering patients' responses to the therapy. According to the prescribing information, ruxolitinib cream is meant for short-term use. For patients who are good candidates for this treatment, the recommended usage is twice daily for eight weeks. After the initial eight-week period, patients and healthcare providers should assess the response to the treatment. If significant improvement is observed, patients should continue using the cream. However, if the desired results are not achieved at that point, it is essential to reevaluate whether ruxolitinib cream is the right treatment option. The indication statement for ruxolitinib cream also mentions "non-continuous chronic use." This refers to the trial program's design, where some patients used the cream on an as-needed basis in the long run. The decision to continue or discontinue the treatment should be based on the individual's response and the discussion between the patient and their healthcare provider in real-world scenarios. Key Points The duration of use depends on the patient's response to the treatment. The prescribing information recommends using it twice daily for eight weeks and assessing the results. If there is improvement, patients should continue using it. If there isn't significant improvement after the initial eight weeks, it's essential to reassess whether this treatment is right for the patient. The indication statement also mentions the possibility of non-continuous chronic use, as seen in the trial program design. In the real world, healthcare professionals will have discussions with their patients about using the cream on an as-needed basis in the long run.

Summary In the video, Dr. Raj Chovatiya explains the recommended dosing regimen for ruxolitinib cream. The cream should be used twice daily and applied to all areas of active atopic dermatitis from head to toe. In clinical trial programs, it has been found effective for various areas of the body, including the head and neck, where traditional treatments might be limited. The cream can be safely used across the skin surface area twice daily, and it is advised not to exceed the usage of one 60-gram tube per week. Key Points Recommended dosing regimen for ruxolitinib cream: Twice daily application Application area: Apply to all areas of active atopic dermatitis from head to toe Common involvement areas in trial programs: Head and neck (limited to approximately 40% of people) • Maximum weekly usage: Not to exceed more than one 60-gram tube per week

Summary In the video, Dr. Raj Chovatiya explains the recommended maximum dosage per week for ruxolitinib cream, considering individual variations in atopic dermatitis severity and body surface area. Generally, the prescribing information suggests twice daily use of the cream, not exceeding one 60-gram tube per week. So, over the course of four weeks (approximately a month), the maximum usage should not exceed four 60-gram tubes. However, the actual amount used may differ based on the individual's body surface area. For example, if someone has less than 10% body surface area affected by atopic dermatitis, one tube might last a long time, while someone with a body surface area in the 10 to 20% range may use the cream more frequently. It's essential for patients to follow their doctor's specific instructions and not exceed the recommended dosage. Key Points Maximum dosage per week recommended for ruxolitinib cream depends on body surface area and the severity of atopic dermatitis. Individual usage may vary based on the person's body surface area. If someone has less than 10% body surface area (BSA), one tube may last longer compared to someone with 10 to 20% BSA. The prescribing information suggests twice daily use and up to one 60-gram tube per week. Over the course of four weeks, the maximum usage should not exceed four 60-gram tubes.